Advertisement
News
Subscribe to MDT Magazine News

Dendreon Announces Exercise and Closing of Overallotment Option

February 3, 2011 7:32 am | by Bio-Medicine.Org | Comments

SEATTLE, Feb. 3, 2011 /- Dendreon Corporation (Nasdaq: DNDN ) today announced that the underwriter in its previously announced public offering of 2.875% convertible senior notes due January 15, 2016 (the "Notes") exercised and closed on its overallotment option in full to purchase an...

TOPICS:

Missouri Baptist Medical Center - Only Non-Teaching Hospital in Region to Offer Colorectal Cancer Patients Robotic Surgery

February 3, 2011 7:30 am | by Bio-Medicine.Org | Comments

ST. LOUIS, Feb. 3, 2011 /- Missouri Baptist Medical Center now provides patients with a new, minimally invasive surgical treatment option for colorectal cancer – robotic surgery with the da Vinci®-S™ Surgical System.  Eric D. Lederman, MD, a board certified general...

TOPICS:

Summary Box: CVS Caremark 4th-quarter profit slips

February 3, 2011 6:45 am | by The Associated Press | Comments

THE RESULTS: CVS Caremark Corp. said its fourth-quarter profit slipped because of business lost by its Caremark pharmacy benefits management unit. The company expects better results in 2011, but said operating income at Caremark will continue to decline.THE OUTLOOK: Caremark's income is expected to...

Advertisement

CVS Caremark 4Q profit falls 2 percent

February 3, 2011 5:45 am | by The Associated Press | Comments

Drugstore chain and pharmacy benefits manager CVS Caremark Corp. said Thursday that its profit fell 2 percent in the fourth quarter on lower revenue because of client losses and fewer Medicare prescription drug program members.The company also offered an estimate for adjusted earnings for this...

Lilly and JDRF partner to fund regenerative medicine research in type 1 diabetes

February 3, 2011 5:36 am | by EurekAlert | Comments

(Juvenile Diabetes Research Foundation International) Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing...

TOPICS:

Adapting technology to elderly people

February 3, 2011 5:36 am | by EurekAlert | Comments

(EUREKA) With the numbers of people aged 65 and over growing, the costs to the state to care for or assist them are set to continue rising across the European Union. With this backdrop, two companies have combined their differing expertise, with the help of Eureka funding, to...

TOPICS:

Concert Pharmaceuticals, Walter Reed partner on seizure treatment

February 3, 2011 5:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Concert Pharmaceuticals Inc. today announced that it has signed an agreement to work with the Walter Reed Army Institute of Research to conduct preclinical testing of a Concert drug compound in treating seizures stemming from traumatic brain injuries.

TOPICS:

Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine(2)

February 3, 2011 5:31 am | by Bio-Medicine.Org | Comments

WORCESTER, Mass., Feb. 3, 2011 /- Generex Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: GNBT ), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), announced today that Antigen Express has received a...

TOPICS:
Advertisement

Mednax 4Q profit rises 9 percent on revenue

February 3, 2011 4:45 am | by The Associated Press | Comments

National physician group Mednax Inc. said Thursday that its fourth-quarter profit rose 9 percent on a boost in revenue.Mednax earned $53.8 million, or $1.12 per share, up from $50.4 million, or $1.07 per share, in the same quarter last year. Revenue rose 10.6 percent to $368.5 million from...

Discovery May Lead to Turning Back the Clock on Ovarian Cancer

February 3, 2011 4:38 am | by Georgia Tech Institute of Technology | Comments

Cancer researchers have discovered that a type of regulatory RNA may be effective in fighting ovarian cancer. This new discovery may allow physicians to turn back the clock of the tumor's life cycle to a phase where traditional chemotherapy can better do its job.

Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease

February 3, 2011 4:36 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Feb. 3, 2011 /- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.  This trial was...

TOPICS:

Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering

February 3, 2011 4:36 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J., Feb. 3, 2011 /- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and...

TOPICS:

Valeant Launches Senior Notes Offering

February 3, 2011 4:36 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, Feb. 3, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) (the "Company") announced today that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect subsidiary, launched its offer of approximately $650 million...

TOPICS:

BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc.

February 3, 2011 4:36 am | by Bio-Medicine.Org | Comments

NEWARK, N.J., Feb. 3, 2011 /- BioNeutral Group, Inc. (OTC Bulletin Board: BONU ), a specialty life science technology-based company, today announced the formation of BioNeutral Services, Inc., a wholly owned subsidiary of BioNeutral Group, Inc., and the appointment of Frank Battafarano as...

TOPICS:

Amarin names Huff to lead cholesterol drug commercialization

February 3, 2011 4:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Amarin Corp. plc, an Irish biotech with U.S. research and development headquarters in Mystic, Conn., has named Paul Huff, an industry veteran with cholesterol drug commercialization under his belt, as chief commercial officer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading